vaqta hepatitis a vaccine inactivated 25 units/0.5ml injection syringe
merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.
vaqta hepatitis a vaccine inactivated 50 units/1ml injection vial
merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.
vaqta hepatitis a vaccine inactivated 25 units/0.5ml injection vial
merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.
imogam rabies pasteurized solution
sanofi pasteur limited - rabies immunoglobulin (human) - solution - 150unit - rabies immunoglobulin (human) 150unit - serums
hyperrab sd
padagis israel agencies ltd, israel - rabies immunoglobulin - solution for injection - rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - to be given in conjunction with rabies vaccine as promptly as possible after exposure.
apvma limited use permit 11859- rabies vaccine/ lyssavirus/ bats
apvma permit - rabies virus (inactivated) - vaccine
versiguard rabies, suspension for injection
zoetis belgium s.a. - inactivated rabies virus, strain vnukovo-32 - suspension for injection - minimum 2.0 international unit(s) - rabies virus - cats, cattle, dogs, ferrets, goats, horses, pigs, sheep - immunological - inactivated vaccine
hyperrab s/d (rabies immune globulin- human injection
grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies vaccine and hyperrab s/d should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. hyperrab s/d should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the u.s. public health service advisory committee on immunization practices (acip). [19] every exposure to possible rabies infection must be individually evaluated. the following factors should be considered before specific antirabies treatment is initiated: carnivorous wild animals (especially skunks, foxes, coyotes, raccoons, and bobcats) and bats are the animals most commonly infected with rabies and have caused most of the indigenous cases of human rabies
rabies vaccine inactivated (freeze dried) powder lyophilized for solution for injection and solvent
serum institute of india pvt ltd. - purified rabies antigen - powder lyophilized for solution for injection and solvent - 2,5iu/ml
rabiesbax-fd 2.5iu / 05ml lyophilized powder fro injection im/sc
juventis pharmaceuticals phils. inc. - rabies vaccine (verocell, purified) - lyophilized powder fro injection im/sc - 2.5iu / 05ml